As Obama blinks on Syria, Israel and Saudi Arabia make common cause

September 2, 2013
Jerusalem/Riyadh, Sep 2: If President Barack Obama has disappointed Syrian rebels by deferring to Congress before bombing Damascus, he has also dismayed the United States' two main allies in the Middle East. obama_syria

Israel and Saudi Arabia have little love for each other but both are pressing their mutual friend in the White House to hit President Bashar al-Assad hard. And both do so with one eye fixed firmly not on Syria but on their common adversary — Iran.

Israel's response to Obama's surprise move to delay or even possibly cancel air strikes made clear that connection: looking soft on Assad after accusing him of killing hundreds of people with chemical weapons may embolden his backers in Tehran to develop nuclear arms, Israeli officials said. And if they do, Israel may strike Iran alone, unsure Washington can be trusted.

Neither US ally is picking a fight with Obama in public. Israeli Prime Minister Benjamin Netanyahu said on Sunday that the nation was "serene and self-confident"; Saudi foreign minister Prince Saud al-Faisal simply renewed a call to the "international community" to halt Assad's violence in Syria.

But the Saudi monarchy, though lacking Israel's readiness to attack Iran, can share the Jewish state's concern that neither may now look with confidence to Washington to curb what Riyadh sees as a drive by its Persian rival to dominate the Arab world.

Last year, Obama assured Israelis that he would "always have Israel's back". Now Netanyahu is reassuring them they can manage without uncertain US protection against Iran, which has called for Israel's destruction but denies developing nuclear weapons.

"Israel's citizens know well that we are prepared for any possible scenario," the hawkish prime minister said. "And Israel's citizens should also know that our enemies have very good reasons not to test our power and not to test our might."

That may not reassure a US administration which has tried to steer Netanyahu away from unilateral action against Iran that could stir yet more chaos in the already explosive Middle East.

Israel's state-run Army Radio was more explicit: "If Obama is hesitating on the matter of Syria," it said, "Then clearly on the question of attacking Iran, a move that is expected to be far more complicated, Obama will hesitate much more — and thus the chances Israel will have to act alone have increased."

Israelis contrast the "red line" Netanyahu has set for how close Iran may come to nuclear weapons capability before Israel strikes with Obama's "red line" on Assad's use of chemical weapons — seemingly passed without US military action so far.

'Head of the snake'

Saudi Arabia, like Israel heavily dependent on the United States for arms supplies, is engaged in a historic confrontation with Iran for regional influence — a contest shaped by their leading roles in the rival Sunni and Shia branches of Islam.

Riyadh is a prime backer of Sunni rebels fighting Assad, whose Alawite minority is a Shia offshoot. It sees toppling Assad as checking Iran's ambition not just in Syria but in other Arab states including the Gulf, where it mistrusts Shias in Saudi Arabia itself and in neighbouring Bahrain, Yemen and Iraq.

Saudi King Abdullah's wish for US action against Iran was memorably contained in leaked US diplomatic cables, including one in which a Saudi envoy said the monarch wanted Washington to "cut off the head of the snake" to end Tehran's nuclear threat.

Disappointment with Obama's hesitation against Assad came through on Sunday in the Saudi foreign minister's remarks to the Arab League in Cairo, where he said words were no longer enough.

Riyadh and its allies in the Gulf Cooperation Council (GCC) risk ending up empty-handed in their latest push for US backing in their campaign to rein in Iran, said Sami al-Faraj, a Kuwaiti analyst who advises the GCC on security matters:

"The idea of a punishment for a crime has lost its flavour. We are on the edge of the possibility that military action may not be conducted," he said. "Congress, for sure ... will attach conditions to what is already going to be a limited strike. At the end, we as Gulf allies, may end up with nothing."

Israel does not share the Saudi enthusiasm for the Syrian rebel cause, despite its concern about Assad's role as a link between Iran and Lebanese and Palestinian enemies. The presence in rebel ranks of Sunni Islamist militants, some linked to al-Qaida, worries the Jewish state — though Riyadh, too, is keen to curb al-Qaida, which calls the royal family American stooges.

Egyptian lessons

Saudi and Israeli support for US air strikes in response to Assad's alleged use of poison gas scarcely stands out less amid a global clamour of reproach for Damascus. However, the recent Egyptian crisis saw them more distinctly making common cause in lobbying Washington — since their preference for Egypt's army over elected Islamists was at odds with much of world opinion.

That, too, reflects shared anxieties about the strength of Islamic populism and about Iran, which found a more sympathetic ear in Cairo after the election of President Mohamed Mursi.

Israeli political commentators used terms such as "betrayal" and "bullet in the back from Uncle Sam" when Obama abandoned loyal ally Hosni Mubarak during the popular uprising of 2011.

While some western leaders voiced unease at the army's overthrow of Mursi in July and bloody crackdown on his Muslim Brotherhood, in Israel even Obama's mild rebuke to the generals — delaying delivery of four warplanes to Egypt — caused "raised eyebrows" of disapproval, an official there said.

A "gag order" from Netanyahu kept that quiet, however, as Israel's military kept open the communications with Egypt's armed forces, not least over militant attacks near their desert border, in a manner that has been the bedrock of the US-brokered peace treaty binding Israel and Egypt since 1979.

Unusually, it was Saudi Arabia which was the more vocally critical of Washington's allies over its Egypt policy.

As US lawmakers toyed with holding back aid to the new military-backed government, Riyadh and its Gulf allies poured in many more billions in aid and loans to Cairo.

And Saudi Arabia told Washington defiantly that it would make up any shortfall if the United States dared to turn off the taps: "To those who have declared they are stopping aid to Egypt or are waving such a threat, the Arab and Muslim nations ... will not shy away from offering a helping hand to Egypt," foreign minister Prince Saud said last month.

Discreet diplomacy

More quietly, Israel has been engaged in direct discussions with the White House, urging Obama not to waver in support of Egypt's military and saying it is time to act on Syria.

An official briefed on US-Israeli discussions said Israeli intercepts of Syrian communications were used by Obama administration officials in making their public case that Assad was behind the Aug. 21 gas attacks and must be penalised.

Netanyahu, whose frosty rapport with Obama blossomed into a display of harmony on the president's visit to Israel in March, has ordered his ministers not to criticise Obama publicly after the president's decision to take the Syrian issue to Congress.

A government source said the prime minister told his cabinet on Sunday: "We are in the middle of an ongoing event. It is not over and there are sensitive and delicate issues at play.

"There is no room here for individual comments," he said. "I'm asking you not to behave irresponsibly when it comes to our ally, just so you can grab a fleeting headline."

That did stop Tzachi Hanegbi, a Netanyahu confidant who sits on parliament's defence committee, complaining on "Army Radio" that Obama had delivered further proof to Iran — and North Korea — that "there is no enthusiasm in the world to deal with their ongoing defiance regarding nuclear weaponry".

"To us it says one thing: ... in the words of our sages: 'If I am not for myself, then who is?'"

Israel clearly hopes still that Congress will give Obama the green light for strikes against Assad but is also likely to be wary of deploying its own lobbying power among lawmakers.

That risks being counter-productive and, in any case, the president has made clear that threats to Israel from Syrian chemical weapons are among his own arguments for war.

Concern in Washington over a go-it-alone Israeli strike on Iran are still strong; Israel is unlikely to use the nuclear warheads it is assumed to possess but any strike on its distant and populous enemy would have unpredictable consequences.

As a result, US leaders have beaten a path to Jerusalem — Obama himself in March but also Secretary of State John Kerry several times, relaunching talks with the Palestinians in the process, and General Martin Dempsey, chairman of the US Joint Chiefs of Staff, who made his third visit to Israel last month.

Gadi Shamni, an Israeli military attache in the United States until last year, said that on the Iranian issue, "there were times when we were in the same book, then the same chapter.

"Right now we are on the same page. There is a lot of flow of intelligence and views and understanding."

Militant threat

For all the unease that Israel has about Syria's rebels, who have at times fired into the Israeli-occupied Golan Heights, it is pushing hard against Assad now after learning to live with the Syrian leader and his father over the past 40 years. One Israeli official said the message from Netanyahu was clear:

"There is a man in nominal control of Syria who is using chemical weapons against civilians. That has to be stopped."

That sentiment is echoed in Riyadh. Abdullah al-Askar, chairman of the foreign affairs committee in the Shoura Council, said that US strikes should aim to end Assad's rule.

Askar, who said he was speaking in a personal capacity, told Reuters: "If the attack is just a punishment to show that the international community will not stand for chemical attacks, Assad will just remain in his place and do his bloody work.

"The second scenario is to finish the business."

Mustafa Alani, a Gulf analyst with good connections to Saudi officials, said the kingdom was also warning Washington that a failure to attack Assad would benefit their common enemy al-Qaida: "No action will boost the extremist position," he said, explaining that rebel despair at US inaction on Syria would push more fighters to switch allegiance to Islamist militants.

Paraphrasing what he said was a Saudi argument, Alani said: "Without a punishment of the regime, extremists will enjoy wider support and attract more moderate fighters."

Riyadh already shares rebel frustrations with the shortage of US military aid reaching Syria, despite Obama's commitment in June to step up assistance after poison gas was first used.

A senior US official spoke of a "stable relationship" with Riyadh "on core national security areas". But the official also conceded: "While we do not agree on every issue, when we have different perspectives we have honest and open discussions."

As with Israel over Iran, those are likely to continue.

Robert Jordan, US ambassador to Riyadh in 2001-03, said intelligence chief Prince Bandar bin Sultan and ambassador to Washington Adel Jubeir had been "very outspoken" in their belief the rebels that can be trusted and should get military backing.

Obama denies seeking the "regime change" Riyadh wants. But Jordan added: "It doesn't mean they won't keep pushing for it."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 18,2020

Beijing, Feb 18: A hospital director at the epicentre of China's virus epidemic died on Tuesday, state media said, the latest medical worker to fall victim to the new coronavirus spreading across the country.

The COVID-19 virus, which is believed to have originated in Wuhan late last year, has infected more than 72,000 people and killed nearly 1,900.

Liu Zhiming, the director of Wuchang Hospital in Wuhan, died Tuesday morning after "all-out rescue efforts failed," state broadcaster CCTV reported.

China said last week that six medical workers had died from the virus, while 1,716 have been infected.

Liu's death was initially reported by Chinese media and bloggers shortly after midnight on Tuesday -- but the stories were later deleted and replaced with reports that doctors were still trying to save him.

After initial reports of his death were denied, the hospital told AFP on Tuesday morning that doctors were giving him life-saving treatment.

Liu's death has echoes of that of Wuhan ophthalmologist Li Wenliang, who had been punished by authorities for sounding the alarm about the virus in late December.

Li's death prompted a national outpouring of grief as well as anger against the authorities, who were accused of mishandling the crisis.

People took to social media to mourn Liu on Tuesday, with many users on the Twitter-like Weibo platform drawing critical comparisons between Liu's death and Li's.

In both cases their deaths were initially reported in state media posts -- later deleted -- and their deaths denied, before being finally confirmed again.

"Has everyone forgotten what happened to Li Wenliang? They forcefully attempted resuscitation after he died," one Weibo commenter wrote.

Another commenter said, Liu "already died last night, (but) some people are addicted to torturing corpses".

A hashtag about Liu's death had 29 million views by Tuesday afternoon.

Doctors in Wuhan face shortages of masks and protective bodysuits, with some even wearing makeshift hazmat suits and continuing to work despite showing respiratory symptoms, health workers have told AFP.

Hubei province and its capital Wuhan have been the hardest hit by the virus, accounting for nearly 1,800 of the deaths from the virus so far.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 22,2020

London, Apr 22: The UK government on Tuesday announced a 20 million pounds funding for a University of Oxford project working on developing a vaccine against the novel coronavirus, which is now ready for acceleration as it begins human trials from Thursday.

UK Health Secretary Matt Hancock told the daily Downing Street briefing that the Department for Health was “throwing everything” at trying to find a vaccine because it is a critical aspect of the COVID-19 pandemic fight and lifting the strict lockdown measures in place to curb its spread.

Another 22.5 million pounds is being made available to Imperial College London to support its phase-two clinical trials for them to begin the work on a very large phase three trial.

"Normally it would take years to get to this point," said Hancock.

"The UK is at the forefront of the global effort – we've put in more money than any other into the global search for a vaccine. Nothing about this is inevitable. Vaccine production is a matter of trial and error. But the UK will throw everything it has at trying to find one,” he said.

The announcement came as Britain had another major daily leap in the hospital death toll from coronavirus, up by 823 to hit 17,337 on Tuesday.

But the Cabinet minister said the government's plan to control the rapid spread of the virus and prevent the state-funded National Health Service (NHS) from being overwhelmed is working as the number of hospitalisations with COVID-19 was showing a downward trajectory.

In reference to a major issue in the last few weeks of a critical shortage of personal protective equipment (PPE) for doctors and nurses on the frontlines of COVID-19 treatment, the minister said the supply problems are being addressed by actively engaging with thousands of companies, including 159 UK manufacturers.

“We are determined to get people the PPE they need. This is a 24/7 operation, one of the biggest cross-government operation I have ever seen," said Hancock.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.